228 results on '"Palermo, Pietro"'
Search Results
2. Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways
3. Influence of exertional oscillatory breathing and its temporal behavior in patients with heart failure and reduced ejection fraction
4. The importance of re-evaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database
5. Pick Your Threshold: A Comparison Among Different Methods of Anaerobic Threshold Evaluation in Heart Failure Prognostic Assessment
6. Symptomatic post COVID patients have impaired alveolar capillary membrane function and high VE/VCO2.
7. Activities of daily living in heart failure patients and healthy subjects: when the cardiopulmonary assessment goes beyond traditional exercise test protocols
8. “Under the Bridge”: Looking for Ischemia in a Patient with Intramyocardial Coronary Artery Course—The Role of the Cardiopulmonary Exercise Test
9. Heart failure and anemia: Effects on prognostic variables
10. Effects of β2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial
11. Heart failure patients with improved ejection fraction: Insights from the MECKI score database.
12. Activities of daily living in heart failure patients and healthy subjects:when the cardiopulmonary assessment goes beyond traditional exercise test protocols
13. Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias
14. The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study
15. 356 DAPAGLIFLOZIN USE IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS: A SINGLE CENTRE COMPARISON BETWEEN REAL-LIFE AND DAPA-HF DATA
16. 166 IMPACT OF PERSONAL PROTECTIVE MASKS ON CARDIORESPIRATORY VARIABLES IN HEALTHY SUBJECTS AND PATIENTS WITH HEART FAILURE: AN INTERIM ANALYSIS
17. 88 INCIDENTAL DIAGNOSIS OF MASSIVE MOBILE LEFT VENTRICLE THROMBI FOLLOWING COVID-19 INFECTION IN A HEART FAILURE PATIENT
18. 141 DIFFERENT KINETICS OF NT-PROBNP AND S-ST2 HIGHLIGHT DIFFERENT THERAPEUTIC THERAPEUTIC PATHWAYS OF SACUBITRIL/VALSARTAN
19. Pick Your Threshold
20. Mediterranean diet impact on cardiovascular diseases: a narrative review
21. ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism
22. Can β-blockers influence regular daily physical activity?
23. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial
24. Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach
25. Hemodynamic Effects of Exercise Training in Heart Failure
26. Effects of β-blockers on ventilation efficiency in heart failure
27. ORIGINAL RESEARCH—ERECTILE DYSFUNCTION: Erectile Dysfunction in Heart Failure: Correlation with Severity, Exercise Performance, Comorbidities, and Heart Failure Treatment
28. Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation
29. Alveolar Membrane Conductance Decreases as BNP Increases During Exercise in Heart Failure. Rationale for BNP in the Evaluation of Dyspnea
30. Respiratory Effects of β-blocker Therapy in Heart Failure
31. “You can leave your mask on”: effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise
32. Minute ventilation/carbon dioxide production in chronic heart failure
33. The MECKI score initiative: Development and state of the art
34. Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude
35. Chronotropic Incompentence and Functional Capacity in Chronic Heart Failure: No Role of β-Blockers and β-Blocker Dose
36. Cardiac patient care during a pandemic: how to reorganise a heart failure unit at the time of COVID-19
37. When should cardiovascular prevention begin? The importance of antenatal, perinatal and primordial prevention
38. Relationship of resting hemoglobin concentration to peak oxygen uptake in heart failure patients
39. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study
40. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison
41. Lateral Decubitus Position Generates Discomfort and Worsens Lung Function in Chronic Heart Failure
42. Erectile Dysfunction in Heart Failure: Correlation with Severity, Exercise Performance, Comorbidities, and Heart Failure Treatment
43. Exercise capacity in patients with β-thalassaemia intermedia
44. Spironolactone improves lung diffusion in chronic heart failure
45. Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients*
46. Prognostic role of beta-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database
47. Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure
48. When should cardiovascular prevention begin? The importance of antenatal, perinatal and primordial prevention.
49. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study
50. Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.